In Brief: Mallinckrodt/MBI
This article was originally published in The Gray Sheet
Executive SummaryMallinckrodt/MBI: File EU marketing application for FS069, the firms' cardiovascular ultrasound contrast agent designed to enhance visualization of endocardial borders and left ventricular opacification, and to improve doppler signal enhancement. A premarket approval application for FS069 is under review at FDA. The agency's Radiological Devices Panel voted 6-1 to recommend that FDA approve the agent without conditions at its meeting earlier this month ("The Gray Sheet" March 3, p. 9)...
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
No device-related warning letters were released by the US FDA the week of 19 February.
Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.